I would agree, with Right To Try coming up in both senate and house--with more than 40 supporters in each branch. I appears a 'cautionary tale' as the FDA is delayed in issuing guidance--and once given the 'right' people will flock towards all sorts of treatment centers. Stem Cell/Regenerative Med, is ahead of the curve and therefore the one that will receive the reprimand first.
I think other 'holistic' and 'therapuetic/homeopathic' centers will be next.
US stem cell was an easy target--as they were already in the rdat process.
News 
Market Data 
Discover 
AI
